Showing 1131-1140 of 4012 results for "".
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
https://reachmd.com/programs/cme/transforming-care-in-pediatric-patients-with-c3-glomerulopathy-targeting-c3-at-the-source/54143/Join Drs. Daga and Lafayette for a case discussion exploring the optimal use of complement inhibitor therapy in a pediatric patient with C3 glomerulopathy.Improving Preventive Care of Patients With Hepatic Encephalopathy: Navigating the Subtleties and Beyond
https://reachmd.com/programs/cme/improving-preventive-care-of-patients-with-hepatic-encephalopathy-navigating-the-subtleties-and-beyond/36305/Learn how PCPs can identify early signs of hepatic encephalopathy to support timely diagnosis and clinical management.Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/Dr. Jennifer Brown discusses CLL treatment sequencing after frontline failure, including resistance vs intolerance, MRD-guided strategies, and second-line therapy decisions.Personalizing First-Line Therapy for CLL
https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/Experts explore first-line therapy selection in CLL, including biomarker testing, time-limited vs continuous regimens, safety profiles, and recent trial data.Beyond Cognition: Managing Alzheimer’s as an Integrated Neurodegenerative–Neuropsychiatric Syndrome
https://reachmd.com/programs/cme/Beyond-Cognition-Managing-Alzheimers-as-an-Integrated-Neurodegenerative-Neuropsychiatric-Syndrome/54842/Examine integrated neurodegenerative and neuropsychiatric features of Alzheimer’s disease, including NPS biology and therapeutic strategies.From Resistance to Response: Evolving Strategies in MDD Management
https://reachmd.com/programs/cme/from-resistance-to-response-evolving-strategies-in-mdd-management/32847/Learn how to better recognize symptoms of major depressive disorder and explore novel therapeutic options for treatment.Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
https://reachmd.com/programs/cme/living-with-systemic-mastocytosis-bridging-clinical-decisions-and-patient-realities/54389/Join us to explore the disease burden of systemic mastocytosis, evidence-based personalized care, and using multidisciplinary strategies to improve outcomes.How COVID-19 Is Affecting Children Physically, Mentally, & Emotionally
https://reachmd.com/programs/covid-19-frontlines/how-covid-19-is-affecting-children-physically-mentally-emotionally/11634/From the newly recognized condition known as MISC to anxiety, a pediatrician shares all the different ways the pandemic is affecting young patients.Diving into Social Determinants of Health & How They Impact Patients
https://reachmd.com/programs/clinicians-roundtable/diving-into-social-determinants-of-health/12115/What are some social determinants of health, and how do we approach them?Future Treatment Options for Hepatitis C
https://reachmd.com/programs/clinicians-roundtable/future-treatment-options-for-hepatitis-c/1947/The future of hepatitis C treatment looks bright -- most likely with the new oral, protease and polymerase inhibitors currently in development. Although these agents represent an exciting phase in the development of effective hepatitis C therapy, they are still a few years away from being recommend